Skip to content
Review Open access

124I-Evuzamitide Positron Emission Tomography/Computed Tomography for Diagnosing Cardiac Amyloidosis: The REVEAL Nonrandomized Clinical Trial.

Aug 2026 · Journal of the American Medical Association (JAMA) · 0 citations · 32 references
Medicine

TL;DR

Results support 124I-evuzamitide PET/CT as a diagnostic test to evaluate patients with suspected cardiac amyloidosis and support 124I-evuzamitide PET/CT as a diagnostic test to evaluate patients with suspected cardiac amyloidosis.

Abstract

Importance Diagnosing cardiac amyloidosis remains challenging because current imaging approaches are limited to transthyretin amyloidosis. A noninvasive test capable of directly imaging cardiac amyloidosis from various amyloid types and in multiple organs could address an important unmet diagnostic need. Objective To evaluate the sensitivity and specificity of 124I-evuzamitide positron emission tomography (PET)/computed tomography (CT) for diagnosing cardiac amyloidosis. Design, Setting, and Participants Prospective, multicenter (18 US centers), single-group study evaluating the efficacy of 124I-evuzamitide to diagnose cardiac amyloidosis. This study was conducted from January 14, 2025, to March 12, 2026, including a 60-day follow-up period. Three physicians with cardiac PET/CT experience independently reviewed PET/CT images for visual cardiac 124I-evuzamitide uptake while blinded to clinical data. Three expert clinical amyloidosis physicians, blinded to PET/CT data, independently adjudicated the diagnosis based on the standard-of-care diagnostic algorithm. A total of 195 adults suspected of having cardiac amyloidosis were enrolled when they presented for diagnostic evaluation at participating institutions, excluding patients with an established diagnosis of cardiac or systemic amyloidosis. Interventions PET/CT scans were obtained 3 to 5 hours after intravenous administration of 1 mCi of 124I-evuzamitide. Potassium iodide (130 mg) was given orally for 3 days starting at least 30 minutes prior to 124I-evuzamitide injection. Main Outcomes and Measures Coprimary end points of this study were to assess the sensitivity and specificity of 124I-evuzamitide for the diagnosis of cardiac amyloidosis. Results Overall, 170 patients were included (median [IQR] age, 72 [64-79] years; 75.3% male, 19.2% Black, 79.0% White). Median N-terminal pro-brain natriuretic peptide was 471 pg/mL and 61.7% had New York Heart Association class II or III heart failure symptoms. The overall sensitivity was 94% (95% CI, 85%-98%; P < .001); specificity, 86% (95% CI, 77%-92%; P < .001); positive predictive value, 85% (95% CI, 75%-92%); and negative predictive value, 94% (95% CI, 87%-98%). Conclusions and Relevance 124I-evuzamitide PET/CT is highly sensitive and specific for diagnosing cardiac amyloidosis with an acceptable safety profile. These results support 124I-evuzamitide PET/CT as a diagnostic test to evaluate patients with suspected cardiac amyloidosis. Trial Registration ClinicalTrials.gov Identifier: NCT06788535.

Read PDF

Similar papers

Open access Sep 2026

Diagnostic Sensitivity of [18F]-Florbetaben-PET/CT in Detecting Cardiac Involvement in AL Amyloidosis

Background Early detection of cardiac involvement in light-chain (AL) amyloidosis remains challenging despite its prognostic importance. [18F]-florbetaben positron emission tomography/computed-tomography (F-PET) shows promise for amyloid detection. Objectives The authors report results from the prospective MoRBiDA (Mol...

P. Milani, G. Sanna, G. Pepe et al. · 0 citations
Review Aug 2026

Diagnostic Accuracy of Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography in Differentiating Tumor and Bland Thrombus in Patients With Cancer: A Systematic Review and Meta-Analysis.

PET/CT scan may be beneficial in distinguishing tumor from bland thrombus in cancer patients and positive and negative likelihood ratios (LR+ and LR-) and diagnostic odds ratio (DOR) were derived from the pooled estimates.

Basant Eltaher, Amir Mahmoud, Kavya Balusu et al. · 0 citations
Oct 2026

18F-FDG PET/CT Metabolic Patterns in Clinically Probable Seronegative Autoimmune Encephalitis with Normal MRI Findings: A Retrospective Observational Study.

Seronegative autoimmune encephalitis (AIE) poses a significant diagnostic challenge because of the absence of identifiable neuronal antibodies and frequently normal structural neuroimaging. 18F-FDG PET/CT has emerged as a sensitive functional imaging modality for detecting metabolic abnormalities in such patients. We c...

Priyanka Verma, Keerti Sitani, Shilpa D. Kulkarni et al. · 0 citations
Open access Oct 2026

Impact of Extracardiac [18F]FDG-PET/CT Findings on Diagnosis and Management in Patients with Suspected Infective Endocarditis

Background/Objectives: We aimed to evaluate the incremental diagnostic and clinical impact of extracardiac findings detected by [18F]Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography ([18F]FDG-PET/CT) in patients with suspected infective endocarditis (IE). Methods: This monocentric cohort study includ...

J. Regina, C. Kamani, D. Rotzinger et al. · 0 citations
Open access Oct 2026

Frequency of Late Gadolinium Enhancement-Negative Cardiac Magnetic Resonance Imaging at Initial Presentation with Metabolically Active Treatment-Naïve Cardiac Sarcoidosis

The 2024 American Heart Association statement recommends fluorine-18 fluorodeoxyglucose (FDG) positron emission tomography (PET) for patients with high clinical suspicion of cardiac sarcoidosis even without late gadolinium enhancement (LGE) on cardiac magnetic resonance (CMR), but this recommendation has been cha...

Y. Kadoya, M. Omaygenc, Bethlehem Mengesha et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.